[go: up one dir, main page]

US20090098061A1 - Solution for tissue adhesion prevention and method for tissue adhesion prevention - Google Patents

Solution for tissue adhesion prevention and method for tissue adhesion prevention Download PDF

Info

Publication number
US20090098061A1
US20090098061A1 US11/917,026 US91702606A US2009098061A1 US 20090098061 A1 US20090098061 A1 US 20090098061A1 US 91702606 A US91702606 A US 91702606A US 2009098061 A1 US2009098061 A1 US 2009098061A1
Authority
US
United States
Prior art keywords
solution
adhesion prevention
tissue adhesion
fluids
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/917,026
Other languages
English (en)
Inventor
Shigeki Suzuki
Yoshikatsu Miwa
Nobuo Sasaki
Yuiichi Tei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
University of Tokyo NUC
Cellex KK
Otsuka Pharmaceutical Factory Inc
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
University of Tokyo NUC
Cellex KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, University of Tokyo NUC, Cellex KK filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Assigned to CELLEX K.K., KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO, THE UNIVERSITY OF TOKYO reassignment CELLEX K.K. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SASAKI, NOBUO, TEI, YUICHI, MIWA, YOSHIKATSU, SUZUKI, SHIGEKI
Publication of US20090098061A1 publication Critical patent/US20090098061A1/en
Assigned to OTSUKA PHARMACEUTICAL FACTORY, INC. reassignment OTSUKA PHARMACEUTICAL FACTORY, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CELLEX K.K
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • This invention relates to a solution for tissue adhesion prevention and a method for tissue adhesion prevention, especially to the solution for tissue adhesion prevention and the method for tissue adhesion prevention composed of trehalose, and that prevents dehydration and oxidation upon exposure to air associated with surgery, and that can prevent complications such as tissue adhesion including postoperative organs.
  • tissues including organs are exposed to air due to incision in surgery, and these tissues can be dehydrated and oxidized leading to their damages.
  • the dehydration and oxidation of tissue including organs during surgery lead to their damages, which are considered as a cause of problems including postoperative tissue adhesion and delay of cure.
  • adhesion especially often inhibits normal movement of tissues including organs, it is considered as one of serious complications after surgery. For instance, the adhesion occurred during tendon surgery may cause dyskinesia. In addition, the organ adhesion after intra-abdominal surgery may cause complications such as ileus, pain and sterility, and sometimes can cause problems such that next surgery becomes very difficult.
  • Examples of current treatment for prevention of tissue adhesion after surgery and delay of cure include treatment in which saline solution is regularly perfused to exposed organs during surgery and treatment in which tissues such as organs are covered with gauze soaked with saline solution.
  • adhesion preventives composed of chitin, adhesion preventives composed with bridged hyaluronic acid and drugs for prevention of delay of cure have been proposed (for instance, refer to Patent documents 1 and 2).
  • trehalose since trehalose has a similar structure to the cluster structure of H 2 O, when administered to cell surface, it is considered to persist as glass (amorphous) condition after dehydration, stabilizing cells or proteins instead of H 2 O and inhibiting these degenerations.
  • Trehalose having such a high performance, is expected to be used for unknown effective indications, and a novel indication for trehalose has been researched in various way.
  • drugs containing trehalose administered to a mucous membrane such as Patent document 3
  • nutrient solutions containing trehalose as a saccharide calorie such as Patent documents 4 and 5
  • solutions for transplanted organ containing trehalose such as Patent document 6
  • intraocular perfusion/washing agents such as Patent document 7
  • association-forming agents between trehalose and unsaturated compounds used for inhibition of chemical changes of unsaturated compounds such as Patent document 8
  • inhibitors of lipolysis degradation containing trehalose such as Patent document 9
  • the objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient.
  • Another objective of the invention is to provide a novel solution for tissue adhesion prevention and a novel method for tissue adhesion prevention using trehalose.
  • the invention is based on the discovery of novel effect of trehalose, and solves the problems described above by composing a solution for tissue adhesion prevention composed of solution of which active ingredient is trehalose. And protection property of tissue is further improved when the solution for tissue adhesion prevention includes glycosyl-L-ascorbic acid.
  • Claim 1 of the invention is characterized by being the solution for tissue adhesion prevention of which active ingredient is trehalose.
  • tissue adhesion prevention prevents dehydration of tissues including wounds and organs exposed to air during surgery as well as inhibits oxidative stress leading to prevention of lipid peroxidation and lipid degradation, and even when wound and tissues are exposed to air during surgery, trehalose forms chelate with metals such as Fe and deactivates metal ion that would cause production of free radicals and therefore inhibits production of free radicals, leading to prevention of tissue adhesion after surgery and delay of wound cure.
  • the solution for tissue adhesion prevention includes at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salt of polysaccharides and salt of mucopolysaccharides having lubricating properties.
  • the tissue protection property of trehalose and the free radical removal property of antioxidants are synergistically exerted to further prevent and inhibit of dehydration and oxidative stress of tissues including wounds and organs during surgery and to reduce production of free radicals.
  • it includes chelates it becomes possible to metabolize by conjugating divalent Fe ion with chelates, and to further reduce production of free radicals.
  • the solution for tissue adhesion prevention of the invention is composed such that it already includes at least one or more among antiseptics, hemostatics and anti-inflammatory agents, it is convenient not being necessary to administer separately drugs such as antiseptics, hemostatics and anti-inflammatory agents.
  • the antioxidant described above is derivative of ascorbic acid.
  • tissue protection property of trehalose and the free radical removal property of derivative of ascorbic acid are synergistically exerted to further prevent and inhibit of dehydration and oxidative stress of tissues including wounds and organs during surgery and to reduce production of free radicals.
  • viscosity of the solution for tissue adhesion prevention is adjusted by thickeners.
  • the osmolarity of the solution is adjusted by at least one or more among isotonic electrolyte solutions, plasma expanders, extracellular replacement fluids, maintenance fluids or water.
  • the solution for tissue adhesion prevention of the invention can be isotonically adjusted and it becomes possible to give the nutrients of these components to applied tissues of the solution for tissue adhesion prevention.
  • solution for tissue adhesion prevention described above is provided as a form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid.
  • the solution for tissue adhesion prevention is provided as a perfusion fluid, it is able to inhibit or prevent impairments of various tissues including adhesion by perfusing during or after surgery with the perfusion fluid of the invention.
  • the solution for tissue adhesion prevention when provided as a spray fluid, it is able to deliver widely and uniformly the solution for tissue adhesion prevention to intended site during surgery as well as to cover the intended site where impairment would be prevented with a sufficient thickness of the solution.
  • the solution of the invention is able to prevent damages of tissue and adhesion of tissues after surgery with a fair degree of certainty by ensuring covering of the intended sites.
  • the solution for tissue adhesion prevention described above when provided as a solution for spray or vaporization administration, the solution for tissue adhesion prevention can be sprayed to the intended sites as a mist, and it become possible to deliver widely and uniformly the solution as a refined mist during surgery as well as to cover the intended site where impairment would be prevented with a sufficient thickness of the solution.
  • the solution of the invention is able to prevent damages of tissue and adhesion of tissues after surgery with a fair degree of certainty by ensuring covering of the intended sites.
  • the solution for tissue adhesion prevention described above is provided as a foam-like aerosol preparation, it is able to deliver widely and uniformly the solution for tissue adhesion prevention to intended site during surgery as well as to cover the intended site where impairment would be prevented with a sufficient thickness of the solution.
  • the solution of the invention is able to prevent damages of tissue and adhesion of tissues after surgery with a fair degree of certainty by ensuring covering of the intended sites.
  • the solution for tissue adhesion prevention described above is provided as a injection solution for intravenous fluids or intravenous fluid, it becomes possible to administer the solution for tissue adhesion prevention by means including intravenous administration during at least one or more processes among before, during and after surgery, and also to prevent or inhibit delay of cure after surgery by means including intravenous administration.
  • the invention is characterized by being a method for tissue adhesion prevention by applying any solution for tissue adhesion prevention described above to local tissue.
  • the solution for tissue adhesion prevention of which active ingredient is trehalose is characterized by being the solution for tissue adhesion prevention of which active ingredient is trehalose.
  • tissue adhesion prevention prevents dehydration of tissues including wounds and organs exposed to air during surgery as well as inhibits oxidative stress leading to prevention of lipid peroxidation and lipid degradation, and even when wound and tissues are exposed to air during surgery, trehalose forms chelate with metals such as Fe and deactivates metal ion that would cause production of free radicals and therefore inhibits production of free radicals, leading to prevention of tissue adhesion after surgery and delay of wound cure.
  • the solution for tissue adhesion prevention contains derivatives of ascorbic acid
  • the tissue protection property of trehalose and the free radical removal property of derivative of ascorbic acid are synergistically exerted to further prevent and inhibit of dehydration and oxidative stress of tissues including wounds and organs during surgery and to reduce production of free radicals.
  • FIG. 1 A first figure.
  • the solution for tissue adhesion prevention of the invention is a solution for tissue adhesion prevention of which active ingredient is trehalose. It is administered directly to tissues including wounds and organs during surgery. It relates to the one used as adhesion preventives that prevent tissue adhesion after surgery or therapeutic agents that prevent delay of wound cure.
  • wound referred to injury
  • tissue to body's tissue such as skin, organ, muscle, nerve, cartilage, bone.
  • the solution for tissue adhesion prevention of the invention can be applied to various animals, especially it is suitably used in mammalian species, especially in humans.
  • This example relates to the solution for tissue adhesion prevention and the one used as tissue-covering agent or adhesion preventive that prevent adhesion of tissue after surgery and delay of wound cure, and as therapeutic agent that enhance cure of tissue and wounds after surgery.
  • the solution for tissue adhesion prevention of this example is a solution of which the active ingredient is trehalose.
  • the solution for tissue adhesion prevention of this example is administered to tissue surface being exposed during surgery.
  • tissue surface being exposed during surgery.
  • it can be widely used in not only laparotomy or thoracotomy but also neurosurgical procedures, orthopedic procedures relating to tendon or ligament, hepatic surgery, gynecologic procedures etc.
  • the tissues exposed during surgery include, for instance, except wounds occurred by surgical incision and organs exposed by incision, muscle, nerve, cartilage, bone. Also, it is applicable for bone marrow exposed by orthopedic osteotomy. Furthermore, it has been reported that trehalose inhibits development of nerve degenerative disorders in mice, therefore, it is applicable for cranial nerves and peripheral nerves exposed by neurosurgical procedures.
  • Trehalose is a non-reducing disaccharide that two molecules of glucose bind by 1 to 1 binding.
  • Trehalose is a publicly known substance isolated from rye in 1832 for the first time. It widely presents in the free state in nature including animals, vegetables and microorganisms. It is contained for rich amount in yeasts such as bakers' yeast and brewers, yeast, and it is a saccharide often observed in foods. Also, it is a saccharide relates to various organisms, and it is said that because trehalose is present, insects such as Macrobiotus and Brachionus and vegetables such as Selaginella tamariscina can survive in rigorous condition such as desert.
  • any of hydrated crystal trehalose, anhydrous crystal trehalose, carbohydrate solution containing trehalose, alpha, alpha-trehalose (in the narrow sense), alpha, beta-trehalose (neo-trehalose), beta, beta-trehalose (iso-trehalose) can be used, however, it is suitable when hydrated crystal trehalose or anhydrous crystal trehalose composed of especially alpha, alpha-trehalose (alpha-D-glucopyranosyl-alpha-D-glucopyranoside) is used.
  • any one produced from natural trehalose, starch, maltooligosaccharides, glucoses can be used.
  • derivatives that produce trehalose in vivo after administration can be used instead of trehalose.
  • isotonic electrolyte fluids As solvent for dissolution of trehalose, isotonic electrolyte fluids, plasma expanders or maintenance fluids or water can be used.
  • the isotonic electrolyte fluids refer to electrolyte preparations that are isotonic.
  • the isotonic fluids refer to intravenous fluid that is isotonic, that is, of which the osmolarity is similar with body fluid.
  • isotonic electrolyte fluid for instance, extracellular replacement fluid can be used.
  • the extracellular replacement fluid refers to intravenous isotonic electrolyte fluid used for replacement or adjustment of extracellular fluid in case of depletion of extracellular fluid due to problems such as hemorrhage, diarrhea, and dehydration.
  • extracellular replacement fluid for instance, physiological saline solution (0.9% saline solution), Ringer's acetate, Ringer's lactate can be used.
  • Plasma expanders also refers to plasma extenders being used as intravenous fluid when proteins such as albumin in plasma are lost due to problems such as hemorrhage for its substitute, and contains high-molecular component such as dextran, starch, recombinant albumin.
  • dextran 40 preparation dextran 70 preparation, hydroxyethyl starch (HES) preparation, modified gelatin preparation can be used.
  • HES hydroxyethyl starch
  • Maintenance fluid is an intravenous fluid being used for replacement and maintenance of water/electrolyte when oral intake is impossible or insufficient.
  • As maintenance fluid starting fluid, maintenance fluid, and high-concentration glucose added maintenance fluid can be used.
  • Water acts as solvent for dissolution of trehalose.
  • water for instance, pure water or distilled water can be used. It is suitable for use of sterile distilled water.
  • the concentration of trehalose in the solution for tissue adhesion prevention is suitable when it is more than 10 mM, preferably within 50 to 350 mM.
  • At least one or more among group including antiseptics, hemostatics and anti-inflammatory agents may be added.
  • antiseptics for instance, publicly known antiseptics such as povidone-iodine, potassium peroxomonosulfate, dimethyldidecyl ammonium chloride, as hemostatics, for instance, publicly known hemostatics such as thrombin, sodium alginate, as anti-inflammatory agents, for instance, non-steroid anti-inflammatory drugs are used.
  • antioxidants may be added.
  • water-soluble stable vitamin C can be used as antioxidant.
  • the water-soluble stable vitamin C include derivatives of ascorbic acid classified into pro-vitamin C agents such as glycosyl-L-ascorbic acid (hereinafter refer as AA-2G) and ascorbic acid-2-phosphoric acid (AA-2P).
  • AA-2G also refers as ascorbic acid-2-glucoside that presents in nature and is degraded in vivo by alpha-glucosidase into L-ascorbic acid and D-glucose, developing similar physiological activity to L-ascorbic acid.
  • AA-2G even in high concentration, does not have cell toxicity and its promoting effect of collagen synthesis and promoting effect of cell proliferation and differentiation are significant, which lead to its frequent use not only in food or cosmetic field but also culture of connective tissues such as fibroblasts.
  • AA-2G a series of 2-glucopyranosyl-L-ascorbic acid including 2-O-alpha-D-monoglucopyranosyl-L-ascorbic acid composed by glycosidic linkage of L-ascorbic acid at C-2 position and one or more D-glucose is suitable for use.
  • AA-2G is not limited to glycosyl-L-ascorbic acid as organic acid, and can be any of physiologically acceptable mineral salts and salts of organic acid such as sodium salt, potassium salt, calcium salt, magnesium salt and ammonium salt that liberate glycosyl-L-ascorbic acid in aqueous media.
  • the concentration of AA-2G in the solution for tissue adhesion prevention is suitable to be more than 0.01 mM, preferably within 0.1 to 200 mM. When it is less than 0.01 mM, the cell protection effect can not be expected.
  • antioxidant minerals such as vitamin C, vitamin E, selenium, in vivo antioxidant enzyme such as SOD (super oxide dismutase), catalase, glutathione peroxidase, vegetable-derived antioxidants (SOD-like substances) that contain carotenoids that are lipid-soluble pigment of vegetables such as alpha-carotine, beta-carotine, gamma-carotine, lycopene, xanthophyll, and polyphenols that are contained in flower, leaf, bark, stem such as flavonoid, catechin, tannin, anthocyanin, isoflavon, quercetin, phycocyanobilin, phycoerythrobilin can be used.
  • SOD super oxide dismutase
  • catalase glutathione peroxidase
  • SOD-like substances vegetable-derived antioxidants that contain carotenoids that are lipid-soluble pigment of vegetables such as alpha-carotine, beta-carotine, gamma-carotine, lycopen
  • chelates may be added.
  • DMPS dimercaptopropanolsulfonate
  • DMSA dimercaptosuccinate
  • ALA alpha-lipoic acid
  • EDTA ethylenediaminetetraacetic acid
  • sodium gluconate can be used. Since chelates can be metabolized by conjugating divalent Fe ions, it becomes possible to prevent the newly production of free radical caused by Fe ions, leading to further more effective prevention of adhesion of tissues including organs after surgery and delay of wound cure.
  • At least one of polysaccharides, mucopolysaccharides and the salts thereof and ones having lubricating properties may be added.
  • polysaccharides and the salts thereof for instance, polysaccharides containing carboxyl group or the water-soluble salts thereof or polysaccharides containing carboxyl group bridged by ion bonding or the water-soluble salts thereof can be used.
  • polysaccharides containing carboxyl group carboxymethylcellulose, carboxymethylchitin, carboxymethylchitosan, carboxymethylstarch, alginic acid, pectin, carboxymethyldextran etc. can be used.
  • Mucopolysaccharides include, except for hyaluronic acid (HA) heparin, heparin sulfate, and chondroitin sulfate.
  • sodium salts, alkali metal salts or alkali earth metal salts can be used.
  • hyaluronic acid among polysaccharides, mucopolysaccharides and the salts thereof.
  • mucopolysaccharides such as hyaluronic acid are known to have force to gelate water of hundreds to thousands of its amount and to give water retentivity, viscosity, lubricity to body fluid. If it is added to the solution for tissue adhesion prevention of this example, when covering surface of tissues such as wounds and organs with the solution for tissue adhesion prevention, it is able to give lubricity to the cover layer and to obtain preventive effect of mechanical damages to wounds and tissues.
  • the solution for tissue adhesion prevention of this example is adjusted such that its osmolarity is within 200 to 450 Osm and its pH is within 7 to 8 after mixing the substances described above.
  • the reason why the osmolarity is adjusted within 200 to 450 Osm is to adapt the osmolarity of human body.
  • the reason why the pH is within 7 to 8 is to prevent acidolysis of tissue cells of wounds or organs administered with the solution for tissue adhesion prevention.
  • colloid osmotic pressure adjustment agents such as hydroxyethylstarch, dextranstarch are used.
  • the osmolarity is adjusted low considering the condensation due to dehydration during surgery.
  • the solution for tissue adhesion prevention of this example is adjusted such that the temperature during use would be near body temperature, that is, 35 to 38 degrees C.
  • the solution for tissue adhesion prevention of this example can be administered anytime only before cure of wounds progresses, although it is preferable to administer during surgery or immediately before suture of wounds. Also it can be administered continuously during surgery.
  • the solution for tissue adhesion prevention of this example is administered directly to tissue surface including wounds and organs exposed to air by incision during surgery.
  • the solution for tissue adhesion prevention is impregnated with carriers such as gauze or non-woven fabric, they may cover the tissue surface including wounds and organs.
  • the solution is poured directly to tissue surface including wounds and organs, or after composing the solution for tissue adhesion prevention of this example as spraying solution, it is sprayed with spraying devices.
  • the solution for tissue adhesion prevention as spraying solution to be able to spray it to the intended sites
  • the solution that works as the solution for tissue adhesion prevention of wounds can be sprayed widely and uniformly to the intended sites as wall as the intended site where impairment would be prevented can be covered with a sufficient thickness of the solution.
  • both spray with two fluid nozzles in which solution drops are carried with air or carbon dioxide and spray with one fluid nozzle in which solution becomes tiny particles by pressure can be used.
  • the one fluid nozzle does not use gas for providing drops. Therefore, use of the one fluid nozzle prevents dehydration or oxidation of the tissues including wounds and organs or lowering temperature by heat of evaporation. So, it is preferable from the aspect of prevention of damages of wounds and tissues.
  • the one fluid nozzle includes hollow cone nozzle and full cone nozzle in which the solution is sprayed out in cone shape by rotational flow, nozzle of which angle of spraying cone can be changed, flat nozzle in which the drops sprayed out in plane shape, solid nozzle in which the drops go straight forward, particle spray in which the drops become tiny particles that are all applicable.
  • the solution for tissue adhesion prevention of this example is composed as solution for spray or vaporization administration, and this solution for spray or vaporization administration is administered by spraying the mist atomized with devices such as nebulizer and vaporizer.
  • the solution for tissue adhesion prevention is composed as solution for spray or vaporization administration to spray it to the intended sites in atomized mist state, the solution that works as the solution for tissue adhesion prevention can be sprayed widely and uniformly to the intended sites as wall as the intended site where impairment would be prevented can be covered with a sufficient thickness of the solution.
  • any of ultrasonic ones in which it is atomized by shaking with ultrasonic oscillator, dropping ones in which drops are carried with gas, jet injection ones in which the solution becomes tiny particles under pressure can be used.
  • a device provided heater, ultrasonic oscillator, air blasting fan, spray orifice in which the solution for spray or vaporization administration heated with heater to given temperature is atomized by shaking with ultrasonic oscillator, and the mist obtained by atomizing is sprayed from spray orifice with air blasting fan can be used.
  • a two-phase vaporizer with the solution for tissue adhesion prevention composed of 2 solutions, that is, water and concentrated solution of the solution for tissue adhesion prevention, provided water tank with heater and concentrated solution tank with ultrasonic oscillator can be used.
  • foam-like aerosol preparation by composing the solution for tissue adhesion prevention of this example as foam-like aerosol preparation, and this foam-like preparation can be administered using heater, pressure device, aerosol device provided nozzle.
  • the foam-like aerosol preparation is composed by adding publicly known surfactants to the solution for tissue adhesion prevention already described.
  • the solution for tissue adhesion prevention and the method for tissue adhesion prevention of this example it is possible to prevent complications after endoscopic surgery. That is, using spray device with one fluid nozzle fixed to the top of extension tube, the spray solution composed of the solution for tissue adhesion prevention of this example can be sprayed to the tissues including organs involved in the surgery during or after endoscopic surgery.
  • the extension tube of one fluid nozzle and cable of endoscopic device are fixed each other, operation of spray device is facilitated because the materials inserted into body during endoscopic procedure are unified.
  • the solution for tissue adhesion prevention of this example can be composed as perfusion fluid, intravenous fluid, injection solution for intravenous fluids.
  • the perfusion fluid is composed as a water solution dissolved trehalose and AA-2G in publicly known intravenous fluid such as saline solution and Ringer's solution, and provided packed into intravenous fluid bag.
  • the perfusion fluid is used by substituting and perfusing operation field during or after surgery.
  • Intravenous fluid preparations are prepared by dissolving trehalose with publicly known tonicity agents such as sodium chloride, glycerin and publicly known buffer fluid such as phosphate and acetate in publicly known solvents such as saline solution and Ringer's solution, and provided packed into intravenous fluid bag.
  • the intravenous fluid preparations are used in at least one or more processes among before, during and after surgery using means such as intravenous drip.
  • Injection solution for intravenous fluids are prepared by dissolving trehalose and AA-2G with publicly known tonicity agents such as sodium chloride, glycerin and publicly known buffer fluid such as phosphate and acetate in publicly known solvents such as saline solution and Ringer's solution.
  • publicly known tonicity agents such as sodium chloride, glycerin and publicly known buffer fluid such as phosphate and acetate
  • publicly known solvents such as saline solution and Ringer's solution.
  • This injection solution is used as mixed solution with publicly known intravenous fluid such as glucose injection, xylitol injection, saline solution, dextran 40 injection, amino acid injection, Ringer's solution.
  • publicly known intravenous fluid such as glucose injection, xylitol injection, saline solution, dextran 40 injection, amino acid injection, Ringer's solution.
  • the injection solutions are used in at least one or more processes among before, during and after surgery using means such as intravenous drip by injecting into intravenous fluid.
  • trehalose prevents dehydration of tissues and wounds and also prevents oxidative impairments due to oxidative stress during surgery. Also, trehalose forms chelates with metals such as Fe, deactivates metal ions that cause free radicals, inhibits production of free radicals. By preventing dehydration, oxidative impairments due to oxidative stress and production of free radicals, it becomes possible to prevent adhesion and delay of cure caused by oxidative impairments after surgery.
  • the solution for tissue adhesion prevention of this example contains AA-2G that is antioxidant by adding radicals, it provides a synergistic effect such that wounds and exposed tissues can be protect more efficiently by combination of trehalose and AA-2G that have different mechanisms of action.
  • HepG2 cells human hepatoma-derived cell lines
  • reagent grade chemicals were used for all reagents other than HepG2 cells.
  • sample solution in which HepG2 cells were activated 4 kinds of solution; PBS (+) solution, 2.5 mM AA-2G solution, 132 mM trehalose solution, 2.5 mM AA-2G+132 mM trehalose mixed solution were prepared.
  • a reagent ascorbic acid-2-glucoside (AA2G; Hayashihara Biochemical Labs., Inc.) was dissolved in distilled water to obtain 2.5 mM AA-2G solution.
  • a highly purified hydrated crystal trehalose in powder (Reagent trehalose; Hayashihara Biochemical Labs., Inc.) was dissolved in distilled water to obtain 132 mM trehalose solution.
  • the reagents ascorbic acid-2-glucoside and the highly purified hydrated crystal trehalose in powder were dissolved in distilled water to obtain 2.5 mM AA-2G+132 mM trehalose mixed solution. Then, pH and osmolarity of these 4 kinds of sample solutions were adjusted.
  • Adjustment of osmolarity of 2.5 mM AA-2G solution, 132 mM trehalose solution, 2.5 mM AA-2G+132 mM trehalose mixed solution was performed by adjusting with sodium chloride of PBS (+) to be isotonic.
  • pH and osmolarity of each sample after adjustment were as follows; pH 7.2 and 279 mOsm for PBS (+) solution, pH 6.8 and 265 mOsm for 2.5 mM AA-2G solution, pH 7.2 and 283 mOsm for 132 mM trehalose solution and pH 7.0 and 282 mOsm for 2.5 mM AA-2G+132 mM trehalose mixed solution.
  • HepG2 cells were seeded with 4 ⁇ 10 4 cells/well each to four 12-well plates, and incubated in DMEM media (Nissui Pharmaceutical Co., Ltd) containing 10% FCS (Gibco) for 4 days. Then the DMEM media containing 10% FCS were replaced with 4 kinds of sample solutions; PBS (+) solution, 2.5 mM AA-2G solution, 132 mM trehalose solution, 2.5 mM AA-2G+132 mM trehalose mixed solution, and activated at 37 degrees C. for 1 hour.
  • Two control plates and two test plates were prepared for cells activated with 4 kinds of sample solutions, respectively. For each two test plates, one plate was air-dried for 5 minutes and other plate was air-dried for 3 minutes. The two control plates were not air-dried.
  • the absorbance of the control plates to which air-dry was not performed was considered as cell survival rate of 100%, and the cell survival rate of the test plates to which air-dry was performed for 3 minutes was calculated. The results are shown in the graph indicating changes in cell survival rate by air-dry in FIG. 1 .
  • the cell survival rates in test plates to which air-dry were performed for 3 minutes were 60.4%, 61.8%, 70.7% and 72.3% for PBS (+) solution, 2.5 mM AA-2G solution, 132 mM trehalose solution and 2.5 mM AA-2G+132 mM trehalose mixed solution, respectively.
  • the cell survival rates of the test plate to which air-dry was performed for 5 minutes for PBS (+) solution was 54.9%.
  • the cell protection effect was calculated for each sample solution considering the cell survival rate of the control plate as 100%, the cell protection effect was not observed for 2.5 mM AA-2G solution, and the cell protection effect was observed for 132 mM trehalose solution and 2.5 mM AA-2G+132 mM trehalose mixed solution when the plates were air-dried for 3 minutes.
  • the cell protection effect from air-dry of these reagents is considered to be effective for slight dehydration of approximately 3 minutes.
  • the cell survival rates in control plates when the cell survival rate of control plate for PBS (+) was considered to be 100%, were 101.6%, 97.6% and 89.6% for 2.5 mM AA-2G solution, 132 mM trehalose solution and 2.5 mM AA-2G+132 mM trehalose mixed solution, respectively.
  • abdominal adhesion model was prepared using rabbits by desiccating surface of intestines during abdominal surgery, and the preventive effect of intestine adhesion by trehalose was discussed.
  • powder trehalose Reagent trehalose; Hayashihara Biochemical Labs., Inc.
  • +NaCl were dissolved in sterile distilled water of 250 mL as 2% solution, sterilized by filtration with filter (Millex; Millpore Co., Bedford) and poured to sterile container and stored at room temperature.
  • filter Millex; Millpore Co., Bedford
  • As test animals five female New Zealand White rabbits weighing 2.85 to 3.2 kg aged of 14 weeks (Std:NZW, Japan SLC, Inc., Shizuoka) were used. The rabbits were kept in animal laboratory (room temperature of 24+/ ⁇ 1 degrees C., humidity of 30 to 70%) in The University of Tokyo, graduate School of Agricultural and Life Sciences Veterinary Medical Center.
  • the rabbits were acclimatized for 1 week after purchase, and during this period blood test (complete blood count, BUN, Cre, ALT, ALP) and general x-ray test were performed to confirm that abnormality was not present.
  • blood test complete blood count, BUN, Cre, ALT, ALP
  • general x-ray test were performed to confirm that abnormality was not present.
  • the experiment of this example was performed according to the Manual of animal experiment of University of Tokyo.
  • the 3-0 monofilament nylon fiber (Bear surgical suture; Bear Medic Corporation, Chiba) was used for ovariohysterectomy and closure of abdominal wall, and the 4-0 monofilament polyglyconate fiber (MAXON; Syneture Co., Ltd., Connecticut) was used for subcutaneous tissues and stapler (Manipler AZ-35W; Mani Inc., Tochigi) was used for skin suture. After operation, general condition and wounds were observed and they were killed by overdose of pentobarbital after 2 weeks. The adhesion status in peritoneal cavity was macroscopically observed and recorded as well as tissues of adhesion sites were removed as pathohistological test material and fixed in formalin.
  • Trehalose has high hydrating properties, and trehalose in amorphous state is considered to prevent adhesion by covering serous membrane of intestines and stabilizing cells.
  • abdominal adhesion model was prepared using rabbits by desiccating surface of intestines during abdominal surgery, and the preventive effect on intestine adhesion by trehalose was discussed.
  • powder trehalose (Reagent trehalose; Hayashihara Biochemical Labs., Inc.) were dissolved in sterile distilled water of 250 mL as 7% solution, sterilized by filtration with filter (Millex; Millpore Co., Bed ford) and poured to sterile container and stored at room temperature.
  • test animals 20 female New Zealand White rabbits weighing 2.6 to 3.2 kg aged of 14 weeks (Std:NZW, Japan SLC, Inc., Shizuoka) were used.
  • the rabbits were kept in animal laboratory (room temperature of 24+/ ⁇ 1 degrees C., humidity of 30 to 70%) in The University of Tokyo, graduate School of Agricultural and Life Sciences Veterinary Medical Center.
  • the rabbits were acclimatized for 1 week after purchase, and during this period blood test (complete blood count, BUN, Cre, ALT, ALP) and general x-ray test were performed to confirm that abnormality was not present.
  • the experiment of this example was performed according to the Manual of animal experiment of The University of Tokyo.
  • the experiment of this example was performed as follows. As anesthesia, 5 mg/kg of ketamine (Ketalal 50; Sankyo Lifetech Co., Ltd., Tokyo) and 0.1 mg/kg of medetomidine (Domitol; Meiji Seiyaku Co., Ltd., Tokyo) were intramuscularly injected as preoperative medication, and after intubation maintained with isoflurane (Isoflu; Dainippon Pharmaceutical Co., Ltd., Osaka).
  • enrofloxacin (Baytril; Bayer Medical Ltd., Tokyo) was subcutaneously administered as antibiotics, and during operation 10 mL/kg/hr of lactated Ringer's solution (Fuso; Fuso Pharmaceutical Industries, Ltd., Osaka) was intravenously administered. After operation, single dose of 20 ug/kg of buprenorphine (Lepetan; Otsuka Pharmaceutical Co., Ltd., Tokyo) as analgesics was subcutaneously administered.
  • ECG, ETCO 2 and SpO 2 were monitored and maintained within their normal variations.
  • uterovaginal stump were sutured with 5-0 mono filament polyglyconate suture (MAXON; Syneture Co., Ltd., Connecticut), the 3-0 mono filament polyglyconate suture (MAXON; Syneture CO., Ltd., Connecticut) was used for closure of abdominal wall, and the 4-0 mono filament polyglyconate suture (MAXON; Syneture Co., Ltd., Connecticut) was used for subcutaneous tissues and stapler (Manipler AZ-35W; Mani Inc., Tochigi) was used for skin suture.
  • MAXON mono filament polyglyconate suture
  • MAXON Syneture Co., Ltd., Connecticut
  • the control group (10 rabbits) was left desiccated.
  • the time period of laparotomy was 60 minutes.
  • trehalose solution was sprayed over the whole abdominal cavities every 15 minutes (0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes after starting the operation). The time period of laparotomy was 60 minutes. After operation, general condition and wounds were observed and rabbits were euthanized by excessive administration of pentobarbital two weeks after the operations.
  • Trehalose has high hydrating properties, and is considered to prevent adhesion by covering serous membrane of intestines and stabilizing cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US11/917,026 2005-06-08 2006-06-08 Solution for tissue adhesion prevention and method for tissue adhesion prevention Abandoned US20090098061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005168744 2005-06-08
JP2005-168744 2005-06-08
PCT/JP2006/311501 WO2006132310A1 (ja) 2005-06-08 2006-06-08 組織癒着防止液及び組織癒着防止方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/311501 A-371-Of-International WO2006132310A1 (ja) 2005-06-08 2006-06-08 組織癒着防止液及び組織癒着防止方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/047,551 Division US9155751B2 (en) 2005-06-08 2011-03-14 Solution for tissue adhesion prevention and method for tissue adhesion prevention

Publications (1)

Publication Number Publication Date
US20090098061A1 true US20090098061A1 (en) 2009-04-16

Family

ID=37498506

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/917,026 Abandoned US20090098061A1 (en) 2005-06-08 2006-06-08 Solution for tissue adhesion prevention and method for tissue adhesion prevention
US13/047,551 Expired - Fee Related US9155751B2 (en) 2005-06-08 2011-03-14 Solution for tissue adhesion prevention and method for tissue adhesion prevention

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/047,551 Expired - Fee Related US9155751B2 (en) 2005-06-08 2011-03-14 Solution for tissue adhesion prevention and method for tissue adhesion prevention

Country Status (22)

Country Link
US (2) US20090098061A1 (zh)
EP (1) EP1905443B1 (zh)
JP (1) JP4447640B2 (zh)
KR (1) KR101004551B1 (zh)
CN (1) CN101193645B (zh)
AU (1) AU2006256084B2 (zh)
BR (1) BRPI0610889A8 (zh)
CA (1) CA2611441C (zh)
CY (1) CY1111453T1 (zh)
DE (1) DE602006018936D1 (zh)
DK (1) DK1905443T3 (zh)
ES (1) ES2363674T3 (zh)
HR (1) HRP20110150T1 (zh)
MY (1) MY142987A (zh)
NO (1) NO20080106L (zh)
NZ (1) NZ564399A (zh)
PL (1) PL1905443T3 (zh)
PT (1) PT1905443E (zh)
RU (1) RU2395287C2 (zh)
SI (1) SI1905443T1 (zh)
TW (1) TWI340645B (zh)
WO (1) WO2006132310A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166089A1 (en) * 2005-06-08 2011-07-07 Otsuka Pharmaceutical Factory, Inc. Solution for tissue adhesion prevention and method for tissue adhesion prevention
US20110237542A1 (en) * 2008-12-01 2011-09-29 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US9089584B2 (en) 2009-05-28 2015-07-28 Profibrix B.V. Treatment of tissue adhesion
US20180221532A1 (en) * 2016-02-29 2018-08-09 Kawasumi Laboratories, Inc. Anti-adhesion material
US20200171216A1 (en) * 2017-08-28 2020-06-04 Kawasumi Laboratories, Inc. Adhesion prevention material

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198869B1 (en) * 2007-02-23 2015-09-16 Next 21 K.K. Trehalose for the treatment or prevention of vasospasm
JP5340823B2 (ja) * 2008-06-24 2013-11-13 ナガセ医薬品株式会社 医療用潤滑剤
JP5820807B2 (ja) 2009-05-28 2015-11-24 プロフィブリックス ビー．ヴイ． フィブリンシーラント
JP5685751B2 (ja) * 2009-08-04 2015-03-18 国立大学法人弘前大学 結膜下線維芽細胞増殖抑制剤および結膜下線維芽細胞増殖抑制方法
RU2532671C2 (ru) 2009-09-03 2014-11-10 Хаясибара Ко.,Лтд. ПРЕПАРАТ В ВИДЕ ТВЕРДЫХ ЧАСТИЦ ДИСПЕРСНОЙ ФАЗЫ, СОДЕРЖАЩИЙ БЕЗВОДНУЮ КРИСТАЛЛИЧЕСКУЮ 2-О-α-D-ГЛЮКОЗИЛ-L-АСКОРБИНОВУЮ КИСЛОТУ, СПОСОБ ЕГО ПРОИЗВОДСТВА И ЕГО ПРИМЕНЕНИЯ
JP5856963B2 (ja) 2010-09-07 2016-02-10 株式会社林原 ２−Ｏ−α−Ｄ−グルコシル−Ｌ−アスコルビン酸含水結晶及び２−Ｏ−α−Ｄ−グルコシル−Ｌ−アスコルビン酸含水結晶含有粉末とそれらの製造方法並びに用途
CN103502260B (zh) 2011-03-07 2016-08-17 株式会社林原 含有2-O-α-D-葡萄糖基-L-抗坏血酸无水结晶的粉末的制造方法
AU2012247480B2 (en) 2011-04-27 2016-09-22 Dilon Technologies Inc. Hemostatic compositions
US9480747B2 (en) 2012-01-24 2016-11-01 Bvw Holding Ag Class of anti-adhesion hydrogels with healing aspects
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
AU2014264228A1 (en) 2013-05-07 2015-11-12 Bio Blast Pharma Ltd. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
CN104027341B (zh) * 2014-06-20 2016-08-31 天津嘉氏堂科技有限公司 一种皮肤护理组合物及其制剂
CN104013639B (zh) * 2014-06-20 2016-08-31 天津嘉氏堂科技有限公司 一种具有皮肤修护功能的组合物及其凝胶剂
CN104107189B (zh) * 2014-06-20 2016-08-31 天津嘉氏堂科技有限公司 皮肤护理组合物及其制剂
CN104257687B (zh) * 2014-10-28 2017-02-15 天津嘉氏堂科技有限公司 用于治疗皮肤创伤的组合物及其糊剂
CN104382931B (zh) * 2014-10-28 2017-06-13 天津嘉氏堂科技有限公司 皮肤创面护理组合物
CN104257682B (zh) * 2014-10-28 2016-04-27 天津嘉氏堂科技有限公司 一种创面修护组合物及制剂
FR3036044B1 (fr) * 2015-05-13 2021-04-30 Cha Ling Dispositif de pulverisation de molecules non volatiles et/ou instables a la temperature, methode de pulverisation associee
CN105168211B (zh) * 2015-10-13 2016-11-16 重庆华森制药股份有限公司 一种奥美拉唑钠药物组合物
AU2016352007B2 (en) * 2015-11-12 2022-03-17 Terumo Kabushiki Kaisha Sustained-release topically administered agent
TWI731076B (zh) 2016-05-03 2021-06-21 瑞士商Ｂｖｗ控股公司 多相凝膠
BR112019001894B1 (pt) 2016-08-12 2022-06-14 Biom'up France SAS Kit para preparar uma composição fluida hemostática e método para preparar uma composição fluida hemostática com o kit
KR102039552B1 (ko) * 2017-10-23 2019-11-01 이재혁 상처 부위에 도포되는 발포성 밴드
CN112055599A (zh) 2018-02-15 2020-12-08 比奥马普法国公司 多维止血产品及其制造方法
KR102427018B1 (ko) * 2019-06-11 2022-07-29 재단법인 베스티안재단 피부치료제의 제조방법 및 이로부터 얻어지는 피부치료제
JP2022550570A (ja) 2019-10-01 2022-12-02 シーロス セラピューティクス， インコーポレイテッド トレハロース製剤およびその使用
WO2024014443A1 (ja) * 2022-07-12 2024-01-18 株式会社大塚製薬工場 カプセル化膵島の保存用又は移植用液
WO2025163775A1 (ja) * 2024-01-31 2025-08-07 カルテック株式会社 加湿器の水の添加剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994277A (en) * 1989-10-31 1991-02-19 Pfizer Hospital Products Group, Inc. Use of xanthan gum for preventing adhesions
US5827640A (en) * 1996-06-14 1998-10-27 Biostore New Zealand Limited Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
US6365338B1 (en) * 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7427607B2 (en) * 2002-02-20 2008-09-23 Next21 K.K. Drug administration method

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2948254B2 (ja) 1990-03-06 1999-09-13 ユニチカ株式会社 癒着防止材
BR9305768A (pt) * 1992-01-22 1997-01-28 Novo Nordisk As Fator XIII ativado composiçao e processo para a produçao do fator XIII ativado
JP3572085B2 (ja) 1992-07-10 2004-09-29 味の素ファルマ株式会社 栄養輸液剤
JP3253131B2 (ja) 1992-07-24 2002-02-04 洋巳 和田 移植臓器用溶液
JP3418423B2 (ja) 1993-03-03 2003-06-23 久光製薬株式会社 経粘膜投与用薬剤組成物
JPH06319486A (ja) 1993-03-16 1994-11-22 Hayashibara Biochem Lab Inc エネルギー用糖源とその用途
JP3420851B2 (ja) 1994-12-06 2003-06-30 株式会社資生堂 癒着防止剤
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP2868206B2 (ja) * 1996-04-16 1999-03-10 株式会社オフテクス 消毒および／または防腐のための有害微生物防除用組成物
NZ333030A (en) * 1996-06-14 2000-05-26 Biostore Nz Ltd Compositions comprising solutes selected from raffinose, trehalose, trimethyl amine oxide and betaine, and use for the preservation of living tissues
EP1018866B1 (en) * 1996-06-14 2002-12-04 Biostore New Zealand Limited Compositions and methods for the preservation of living tissues
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
CN1359299A (zh) * 1999-06-02 2002-07-17 人类基因组科学公司 角质细胞生长因子－2制剂
JP2002024832A (ja) 2000-06-30 2002-01-25 Koboruto:Kk 指紋データの管理方法および装置
JP2002047189A (ja) 2000-07-26 2002-02-12 Seishi Yoneda 心停止液
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US20060134140A1 (en) * 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
JP4286480B2 (ja) * 2001-09-17 2009-07-01 株式会社メニコン 殺菌液
CA2488011C (en) * 2002-06-03 2008-02-12 Cac Corporation External preparations for treating dermatitis
JP2004224677A (ja) * 2003-01-20 2004-08-12 Masahiro Nagahama 抗線虫及び病害虫等による食害軽減効果と抗ウイルス効果とを有する肥料組成物
EP1600143B1 (en) * 2003-02-13 2019-07-10 Hayashibara Co., Ltd. SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
WO2004076602A1 (ja) * 2003-02-27 2004-09-10 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 脂質膜を構成している脂質の分解抑制方法及びその用途
KR20060032953A (ko) * 2003-05-08 2006-04-18 셀라티스 에이비 폐쇄된 스트로 초자화 방법의 사용에 의한 인간 배반포에서유래된 줄기 세포의 동결 보존
FR2855177B1 (fr) 2003-05-23 2005-07-08 Raymond Robert Composition contenant des acides nucleiques lyophilises en presence de collagene et de disaccharides
US20060233934A1 (en) 2003-06-05 2006-10-19 Hans Zoerb Beverage additive mixture of trehalose and protein
WO2005115252A1 (ja) 2004-05-13 2005-12-08 Nakanishi Inc. 経内視鏡手術に用いる止血と、癒着の防止装置
US7433759B2 (en) * 2004-07-22 2008-10-07 Applied Materials, Inc. Apparatus and methods for positioning wafers
US20060047005A1 (en) * 2004-08-26 2006-03-02 Salamone Joseph C Compositions containing N,N,N',N'-tetrakis(hydroxyalkyl)diamine-or N,N,N',N'-tetrakis(hydroxyalkoxy)diamine-based buffers
JP2006188672A (ja) * 2004-12-06 2006-07-20 Hayashibara Biochem Lab Inc ラジカル生成抑制剤
MY142987A (en) * 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994277A (en) * 1989-10-31 1991-02-19 Pfizer Hospital Products Group, Inc. Use of xanthan gum for preventing adhesions
US5827640A (en) * 1996-06-14 1998-10-27 Biostore New Zealand Limited Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
US6365338B1 (en) * 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7427607B2 (en) * 2002-02-20 2008-09-23 Next21 K.K. Drug administration method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166089A1 (en) * 2005-06-08 2011-07-07 Otsuka Pharmaceutical Factory, Inc. Solution for tissue adhesion prevention and method for tissue adhesion prevention
US9155751B2 (en) * 2005-06-08 2015-10-13 The University Of Tokyo Solution for tissue adhesion prevention and method for tissue adhesion prevention
US20110237542A1 (en) * 2008-12-01 2011-09-29 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US8703740B2 (en) 2008-12-01 2014-04-22 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US9089584B2 (en) 2009-05-28 2015-07-28 Profibrix B.V. Treatment of tissue adhesion
US20180221532A1 (en) * 2016-02-29 2018-08-09 Kawasumi Laboratories, Inc. Anti-adhesion material
US20200171216A1 (en) * 2017-08-28 2020-06-04 Kawasumi Laboratories, Inc. Adhesion prevention material

Also Published As

Publication number Publication date
JPWO2006132310A1 (ja) 2009-01-08
CN101193645A (zh) 2008-06-04
JP4447640B2 (ja) 2010-04-07
EP1905443B1 (en) 2010-12-15
ES2363674T3 (es) 2011-08-11
HK1113746A1 (zh) 2008-10-17
KR101004551B1 (ko) 2011-01-03
US20110166089A1 (en) 2011-07-07
RU2395287C2 (ru) 2010-07-27
TWI340645B (en) 2011-04-21
US9155751B2 (en) 2015-10-13
AU2006256084A1 (en) 2006-12-14
DE602006018936D1 (de) 2011-01-27
RU2007149561A (ru) 2009-07-20
PL1905443T3 (pl) 2011-05-31
KR20080019054A (ko) 2008-02-29
BRPI0610889A2 (pt) 2010-08-03
EP1905443A4 (en) 2009-12-16
NZ564399A (en) 2010-09-30
CN101193645B (zh) 2010-12-08
SI1905443T1 (sl) 2011-04-29
CA2611441C (en) 2012-03-06
DK1905443T3 (da) 2011-03-28
CA2611441A1 (en) 2006-12-14
MY142987A (en) 2011-02-14
EP1905443A1 (en) 2008-04-02
CY1111453T1 (el) 2015-08-05
WO2006132310A1 (ja) 2006-12-14
AU2006256084B2 (en) 2010-01-28
BRPI0610889A8 (pt) 2017-01-24
PT1905443E (pt) 2011-03-07
TW200722094A (en) 2007-06-16
HRP20110150T1 (hr) 2011-04-30
NO20080106L (no) 2008-01-07

Similar Documents

Publication Publication Date Title
US9155751B2 (en) Solution for tissue adhesion prevention and method for tissue adhesion prevention
EP3060266B1 (en) Chitosan paste wound dressing
AU2014340012A1 (en) Chitosan paste wound dressing
WO2017156418A1 (en) Cationic steroidal antibiotic compositions for the treatment of dermal tissue
CN107708752A (zh) 抗微生物纤维和组合物
KR20070101223A (ko) 페놀성 방부 조성물 및 이의 사용 방법
AU2015352171A1 (en) Prevention and treatment of microbial infections
CN108187132A (zh) 一种聚维酮碘水凝胶抗菌敷料及其制备方法
MX2007014856A (es) Composicion de factor de crecimiento epidermico, un proceso para el mismo y su aplicacion.
US20240108697A1 (en) Antimicrobial compositions
CN111991417A (zh) 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用
HK1113746B (zh) 组织粘连防止液
TW202545544A (zh) 普維酮碘及生物聚合物的藥用組合物及製造其之方法
RO128972A0 (ro) Membrană de colagen cu doxiciclină pentru uz stomatologic şi procedeu de obţinere a acesteia
EA041409B1 (ru) Фармацевтическое средство для лечения артрологических заболеваний
CN116850351A (zh) 一种具有较强抗菌作用的粘弹剂
CN108714168A (zh) 一种外用处理伤口的复合木醋液
UA126254U (uk) Спосіб місцевого лікування зон паранекрозу при глибоких опіках

Legal Events

Date Code Title Description
AS Assignment

Owner name: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SASAKI, NOBUO;TEI, YUICHI;MIWA, YOSHIKATSU;AND OTHERS;REEL/FRAME:020220/0710;SIGNING DATES FROM 20071102 TO 20071107

Owner name: CELLEX K.K., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SASAKI, NOBUO;TEI, YUICHI;MIWA, YOSHIKATSU;AND OTHERS;REEL/FRAME:020220/0710;SIGNING DATES FROM 20071102 TO 20071107

Owner name: THE UNIVERSITY OF TOKYO, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SASAKI, NOBUO;TEI, YUICHI;MIWA, YOSHIKATSU;AND OTHERS;REEL/FRAME:020220/0710;SIGNING DATES FROM 20071102 TO 20071107

AS Assignment

Owner name: OTSUKA PHARMACEUTICAL FACTORY, INC.,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELLEX K.K;REEL/FRAME:024504/0409

Effective date: 20100520

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION